Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Blackburn Rovers aim to continue their strong form against struggling Portsmouth, while QPR and Oxford United face tough tests against resilient opponents.
Novartis raises mid-term sales guidance, citing strong drug performance and promising pipeline, but analysts express concerns about sustaining growth beyond 2029.
Blackburn Rovers aim to continue their strong form against struggling Portsmouth, while QPR and Oxford United face tough tests against resilient opponents.